Next-Gen mRNA Manufacturing
The mRNA revolution is reshaping vaccine scalability, cost, and efficacy, with strong pipeline momentum in therapeutics. Advances in delivery and stability drive adoption, while firms tackle CMC, manufacturing scale-up, and regulatory hurdles.
Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?
I am a Pharmacy graduate, did my Master's in Medicinal Chemistry, and PhD in Chemistry. I have experience in drug discovery and possess deep knowledge in QbD-based downstream process development of viral and bacterial vaccines, proteins, enzymes, and mRNA technology. I have in-depth knowledge of the technology transfer of projects with GMP compliance at commercial scale.
Q2. How is the rapid evolution of mRNA technology changing the benchmarks for scalability, cost, and efficacy in vaccine manufacturing over the next five years?
mRNA technology is rapidly expanding. The process is scalable with minimal modification of existing facilities. The cost of raw materials, nucleotides, and LNPs is increasing by 10-20% annually, as per trend. We need to develop stable LNPS that can be stored in refrigerators—efficacy to be established for specific therapeutic areas.
Q3. Which therapeutic areas are showing the strongest pipeline momentum and investment interest for next-generation mRNA platforms?
Major companies are working on Cancer Vaccines and Immuno-Oncology, Rare Genetic and Metabolic Diseases, and other therapeutic areas.
Q4. How are innovations in mRNA delivery systems and stability enhancement influencing…
Create an account to continue reading
Create AccountAlready have an account? Sign in
Need an expert in this space?
Talk to an Industry Expert
Knowledge Ridge connects decision-makers with carefully vetted subject matter experts for one-on-one calls, research sprints, and advisory engagements — across 11 sectors and 163 sub-industries globally.
Comments
No comments yet. Be the first to comment!